Altheus Therapeutics was established to develop novel therapies for Inflammatory Bowel Disease (IBD).  Our technologies, developed at the University of Oklahoma, are the result of 30 years of research and insight into the disease.  Our product candidates show drastic increase in efficacy versus the current frontline treatment, meaning the potential for less suffering and more active lives for those with the disease. 

Our goal:  to bring to market technologies that address unique disease mechanics of IBD and in turn reduce suffering.